These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38023441)

  • 1. Variation in Medicaid and commercial coverage of cell and gene therapies.
    Beinfeld MT; Rucker JA; Jenkins NB; de Breed LA; Chambers JD
    Health Policy Open; 2023 Dec; 5():100103. PubMed ID: 38023441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Commercial health plans use of patient subgroup restrictions: An analysis of orphan and US Food and Drug Administration-expedited programs.
    Jenkins NB; Rucker JA; Klimchak AC; Sedita LE; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):472-479. PubMed ID: 36864544
    [No Abstract]   [Full Text] [Related]  

  • 3. US commercial health plan coverage dynamics in pulmonary arterial hypertension therapies.
    Rucker JA; Beinfeld MT; Enright DE; Germack HD; Panjabi S; Chakinala MM; Chambers JD
    J Manag Care Spec Pharm; 2024 Jun; 30(6):541-548. PubMed ID: 38824632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
    Panzer AD; Ingham M; Martin S; Chambers JD
    J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
    [No Abstract]   [Full Text] [Related]  

  • 5. Specialty drug coverage varies between health plans' medical and pharmacy benefit policies.
    Levine AA; Panzer AD; Kauf TL; O'Sullivan AK; Strand L; Chambers JD
    J Manag Care Spec Pharm; 2023 Jun; 29(6):607-613. PubMed ID: 37276044
    [No Abstract]   [Full Text] [Related]  

  • 6. Balancing Evidence and Need: Variation in US Commercial Payer Coverage of Esketamine.
    Ochigbo EB; Beinfeld MT; Chambers JD
    Clin Ther; 2024 Oct; 46(10):808-811. PubMed ID: 39039006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in health plan coverage of ESAs for anemia due to chronic kidney disease.
    Margaretos NM; Panzer AD; Lai RC; Sanon M; Michalopoulos E; Redmond AM; Moghadam R; Chambers JD
    J Manag Care Spec Pharm; 2021 Sep; 27(9):1221-1229. PubMed ID: 34464213
    [No Abstract]   [Full Text] [Related]  

  • 8. Use of prescriber requirements among US commercial health plans.
    Lenahan K; Panzer AD; Gertler R; Chambers JD
    J Manag Care Spec Pharm; 2021 Dec; 27(12):1757-1762. PubMed ID: 34818091
    [No Abstract]   [Full Text] [Related]  

  • 9. Coverage of Nonpharmacologic Treatments for Low Back Pain Among US Public and Private Insurers.
    Heyward J; Jones CM; Compton WM; Lin DH; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket MC; Porter L; Tierce JC; Alexander GC
    JAMA Netw Open; 2018 Oct; 1(6):e183044. PubMed ID: 30646222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining US commercial health plans' use of The Institute for Clinical and Economic Review's reports in specialty drug coverage decisions.
    Chambers JD; Enright DE; Panzer AD; Cohen JT; Ollendorf DA; Neumann PJ
    J Manag Care Spec Pharm; 2023 Mar; 29(3):257-264. PubMed ID: 36840954
    [No Abstract]   [Full Text] [Related]  

  • 11. Patients' access to rare neuromuscular disease therapies varies across US private insurers.
    Margaretos NM; Bawa K; Engmann NJ; Chambers JD
    Orphanet J Rare Dis; 2022 Feb; 17(1):36. PubMed ID: 35123543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in access to hemophilia A treatments in the United States.
    Margaretos NM; Patel AM; Panzer AD; Lai RC; Whiteley J; Chambers JD
    J Med Econ; 2021; 24(1):1143-1148. PubMed ID: 34538215
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in Medicaid and commercial payer coverage of aducanumab for Alzheimer's disease.
    Lin PJ; Levine A; Rucker J; Chambers JD
    Alzheimers Dement; 2023 Aug; 19(8):3654-3669. PubMed ID: 36852834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterizing health plan evidence review practices.
    Panzer AD; Enright DE; Graff J; Chambers JD
    J Manag Care Spec Pharm; 2022 Sep; 28(9):1053-1058. PubMed ID: 36001106
    [No Abstract]   [Full Text] [Related]  

  • 15. An early examination of access to select orphan drugs treating rare diseases in health insurance exchange plans.
    Robinson SW; Brantley K; Liow C; Teagarden JR
    J Manag Care Spec Pharm; 2014 Oct; 20(10):997-1004. PubMed ID: 25278322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?
    Chambers JD; Margaretos NM; Enright DE; Wang R; Ye X
    Pharmacoeconomics; 2022 Feb; 40(2):225-232. PubMed ID: 34697718
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Varied use of step therapy among Medicare Advantage plans.
    Jenkins NB; Nichols DE; Enright DE; Chambers JD
    Am J Manag Care; 2023 Sep; 29(9):464-468. PubMed ID: 37729529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
    Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
    JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors Associated with Biosimilar Exclusions and Step Therapy Restrictions Among US Commercial Health Plans.
    Yu T; Jin S; Li C; Chambers JD; Hlávka JP
    BioDrugs; 2023 Jul; 37(4):531-540. PubMed ID: 37004706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in pre-operative insurance requirements for bariatric surgery.
    Gomez-Rexrode AE; Chhabra KR; Telem DA; Chao GF
    Surg Endosc; 2022 Nov; 36(11):8358-8363. PubMed ID: 35513536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.